Dong-dong Li

State Key Laboratory Of Natural Medicines And Jiangsu Key Laboratory Of Drug Design And Optimization
Nanjing, 210009, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.

Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.

Journal: European journal of medicinal chemistry

Published: October 19, 2019

Design, synthesis, and initial evaluation of affinity-based small molecular probe for detection of WDR5.

Design, synthesis, and initial evaluation of affinity-based small molecular probe for detection of WDR5.

Journal: Bioorganic chemistry

Published: September 15, 2017

Targeting protein-protein interaction between MLL1 and reciprocal proteins for leukemia therapy.

Targeting protein-protein interaction between MLL1 and reciprocal proteins for leukemia therapy.

Journal: Bioorganic & medicinal chemistry

Published: September 05, 2017

Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90.

Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90.

Journal: Journal of medicinal chemistry

Published: December 10, 2016

Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification.

Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification.

Journal: Bioorganic & medicinal chemistry

Published: August 31, 2016

Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction.

Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction.

Journal: Bioorganic & medicinal chemistry

Published: August 19, 2016

High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity.

High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity.

Journal: European journal of medicinal chemistry

Published: May 09, 2016

G9a - An Appealing Antineoplastic Target.

G9a - An Appealing Antineoplastic Target.

Journal: Current cancer drug targets

Published: January 26, 2016

Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5.

Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5.

Journal: European journal of medicinal chemistry

Published: July 22, 2015

Showing 1-9 of 9

Last Updated: 09/26/2026